Global InformationOwkin information
 | |
| Industry | Biotechnology |
|---|---|
| Founded | August 3, 2016 |
| Founder | Thomas Clozel, Gilles Wainrib |
| Headquarters | Paris , France |
Area served | US, France, UK, Switzerland, Germany, Spain |
| Products | MSIntuit CRC, RlapsRisk BC |
| Services | AI Drug Discovery, AI Drug Development, AI Diagnostics |
Number of employees | 350 (2023) |
| Website | owkin |
Owkin is an AI biotech company that uses artificial intelligence to identify new treatments, optimize clinical trials and develop AI diagnostics.[1][2] The company uses federated learning, a type of privacy preserving technology, to access multimodal patient data from academic institutions and hospitals to train its AI models for drug discovery, development, and diagnostics. Owkin has collaborated with pharmaceutical companies around the world to improve their therapeutic programs.[3]
- ^ "AI Steps Up to Streamline MSI Testing in Colorectal Cancer". AZoRobotics.com. 2023-11-07. Retrieved 2023-12-14.
- ^ Alston, Fiona (2023-03-31). "French AI biotech unicorn Owkin has launched a €33 million AI-powered precision medicine project for cancer diagnosis and treatment". www.tech.eu. Retrieved 2023-11-01.
- ^ "Amgen, Owkin Use AI to Improve Cardiovascular Risk Prediction". Contract Pharma. Retrieved 2021-12-29.